Cerevel Therapeutics Holdings(CERE) - 2022 Q4 - Annual Report

PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 113 Item 6. Reserved 114 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 114 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 129 Item 8. Financial Statements and Supplementary Data 129 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 129 Item 9A. Controls and Procedures 130 It ...